Lipocine (LPCN) Assets Average (2012 - 2025)
Lipocine's (LPCN) quarterly Assets Average came in at $16.5 million in Q4 2025, down 23.44% YoY from $21.6 million in Q4 2024, and down 4.54% on a QoQ basis from $17.3 million in Q3 2025.
Lipocine (LPCN) Assets Average (2012 - 2025) Analysis & Trends
Lipocine (LPCN) has 14 years of Assets Average data on file, last reported at $16.5 million in Q4 2025.
- Quarterly Assets Average fell 23.44% year-over-year to $16.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.5 million (down 23.44% YoY) and the FY2025 annual result came in at $19.8 million, down 13.17% from the prior year.
- Assets Average fell to $16.5 million in Q4 2025, from $17.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $50.0 million in Q1 2022 to a low of $16.5 million in Q4 2025.
- A 5-year average of $31.9 million and a median of $29.9 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2021 — Assets Average surged 119.79% — and 2023, when it plunged 37.96%.
- Tracing LPCN's Assets Average over 5 years: stood at $46.4 million in 2021, then decreased by 17.13% to $38.5 million in 2022, then sank by 37.96% to $23.9 million in 2023, then decreased by 9.52% to $21.6 million in 2024, then slipped by 23.44% to $16.5 million in 2025.
- The last three Assets Average figures came in at $16.5 million (Q4 2025), $17.3 million (Q3 2025), and $19.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 19.82 Bn |
| 10 | Lipocine | 11.37 Mn | -12.54 Mn | - | 16.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.54 Mn |
| Sep 30, 2025 | 17.33 Mn |
| Jun 30, 2025 | 19.54 Mn |
| Mar 31, 2025 | 21.51 Mn |
| Dec 31, 2024 | 21.60 Mn |
| Sep 30, 2024 | 21.87 Mn |
| Jun 30, 2024 | 24.24 Mn |
| Mar 31, 2024 | 24.22 Mn |
| Dec 31, 2023 | 23.88 Mn |
| Sep 30, 2023 | 27.62 Mn |
| Jun 30, 2023 | 32.25 Mn |
| Mar 31, 2023 | 35.78 Mn |
| Dec 31, 2022 | 38.48 Mn |
| Sep 30, 2022 | 40.81 Mn |
| Jun 30, 2022 | 44.90 Mn |
| Mar 31, 2022 | 50.04 Mn |
| Dec 31, 2021 | 46.44 Mn |
| Sep 30, 2021 | 43.78 Mn |
| Jun 30, 2021 | 48.88 Mn |
| Mar 31, 2021 | 37.96 Mn |